Hemogenyx Pharmaceuticals utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by Hemogenyx Pharmaceuticals’ Co-Founder Dr Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results. A patent for Dr Sandler’s work was issued in the US in February 2020.
Hu-PHEC-based technology presents a number of important advantages compared to other existing and developing technologies. Most of these advantages are rooted in the fact that Hu-PHECs are a naturally occurring cell type found in adult and postnatal mammalian tissues. They can easily be isolated and do not require “heavy” manipulation before use. Hu-PHECs are “healthy” because they do not accumulate blood cancer-related mutations and/or chromosomal rearrangements, making them a perfect candidate for autologous (patient-specific) BM/HSC transplantations. In addition, Hu-PHECs can be propagated in vitro, allowing the introduction of therapeutic genes and gene modifications and making them a prime candidate for curative gene therapy applications.
Hemogenyx Pharmaceuticals is developing Hu-PHEC technology based on cells isolated from two different sources:
Cord blood is extracted from the vessels of the umbilical cord and placenta of a donor using standard methods. To isolate endothelial cells emptied blood vessels of the tissues are treated using a proprietary method developed by Hemogenyx.
To isolate Hu-PHEC, endothelial cells are sorted using fluorescent activated cell sorting (FACS) using proprietary FDA certified reagents developed by Hemogenyx Pharmaceuticals utilizing proprietary methods (patent issued February 2020; No. US 10,570,373 B2). Isolated Hu-PHEC are stored for further use in conjunction with standard cord blood cells for further use in transplantation. When needed, both Hu-PHEC and cord blood cells obtained from the same donor are used for hematopoietic transplantation per existing and widely practiced transplantation protocols.
A liver biopsy is obtained from a patient per existing and widely practiced protocols. Endothelial cells are isolated from a liver biopsy of a patient using a proprietary method developed by HemoGenyx.
To isolate Hu-PHEC, endothelial cells are sorted using fluorescent activated cell sorting (FACS) using proprietary FDA certified reagents developed by Hemogenyx Pharmaceuticals utilizing proprietary methods (patent issued February 2020; No. US 10,570,373 B2). Isolated Hu-PHEC are stored for further use in transplantation. When needed, liver Hu-PHEC are activated and intravenously transplanted to the patient they were obtained from.